Biotechnology

BGI Group Included in First Fortune China ESG List

SHENZHEN, China, Aug. 23, 2022 /PRNewswire/ -- BGI Group is featured among the top companies inChina in Fortune China's inaugural China ESG list, published this week. As Fortune China notes in their introduction to the list of 40 featured companies, they were delighted to find that although...

2022-08-24 23:15 2691

MGI Wins IBO Design Gold Award for DNBelab C4 Pocket Single-Cell Lab

SHENZHEN, China, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has been awarded Gold by Instrument Business Outlook (IBO) at the 2022 IBO Design Awards for the outstanding design and functionality of its DNBelab C4 Pocket Single-Cell Lab. "MGI...

2022-08-24 22:05 2328

AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego

HAMILTON ON, Aug. 24, 2022 /PRNewswire/ -- AtomVie Global Radiopharma Inc. ("AtomVie") today announced the successful closing of its Series A financing with Avego Management, LLC ("Avego"), a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Orga...

2022-08-24 21:00 3294

MGI Supports the Ministry of Health of Indonesia in the Country's Breakthrough National Genome Project

JAKARTA, Indonesia, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, today announced that the National Genome Project inIndonesia has selected MGI technology* as one of the technology providers for the first phase of its effort towards establishin...

2022-08-24 17:34 3349

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ -- The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the ...

2022-08-24 09:00 2642

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2022-08-24 08:00 2996

Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results

Additions to executive team strengthen global leadership and position Company for strategic long-term growth First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 inChina advances Brii Bio from clinical development to commercial stage biotechnology co...

2022-08-24 07:30 3517

MGI Honored with 2022 Stevie® Award for Most Valuable COVID-19 Corporate Response

SHENZHEN, China, Aug. 23, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, was named the winner of a Silver Stevie® Award for Most Valuable Corporate Response in the COVID-19 category as part of the 19th Annual International Business Awards. This marked t...

2022-08-23 18:27 2000

Firmenich Receives SBTi Approval For Net-Zero Emissions Target

Firmenich is the first company in the industry to receive approval from the Science Based Targets initiative (SBTi) for its net-zero emissions target GENEVA, Aug. 23, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, has received approval from the S...

2022-08-23 18:00 1768

Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals

LISBON, Portugal, Aug. 23, 2022 /PRNewswire/ -- Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor...

2022-08-23 17:58 1267

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Building a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock ...

2022-08-23 07:30 3147

AVELOS THERAPEUTICS ANNOUNCES $8 MILLON SERIES A FUNDING ROUND

Seoul-Based Biotechnology Company to Use Financing for Expanding Oncology Drug Discovery and Development SEOUL, South Korea, Aug. 22, 2022 /PRNewswire/ -- Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement ...

2022-08-22 20:00 1758

Prominent ophthalmologist will guide Turn Bio's search for therapies to cure eye diseases

Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA ...

2022-08-22 20:00 2372

Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer

NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leading global R&D biotechnology company, today announced the appointment ofSteven Knapp, PharmD., as Chief Regulatory & Quality Officer. In this position, he is responsible for the strategic leadership...

2022-08-22 13:00 1616

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17

* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can beginonce a policy recommendation from the CDC is received GAITHERSBURG, Md., Aug. 2...

2022-08-22 10:05 2972

World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA

SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 19, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today that the Center for Drug ...

2022-08-19 18:41 1833

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

* Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union * Submission supported by results from the pivo...

2022-08-19 18:15 2161

J INTS BIO successfully held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR TKI (JIN-A02) in Vienna, Austria during WCLC

SEOUL, South Korea, Aug. 19, 2022 /PRNewswire/ -- J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' on the sideline of the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, on 7th August. This follo...

2022-08-19 16:00 991

Angel Yeast Brings Latest Innovative Products and Solutions to FIC 2022

GUANGZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), a globally listed yeast and yeast extract manufacturer, showcased its latest yeast and yeast extract products, health ingredients, and fermentation ingredients alongside its wide range of innova...

2022-08-19 15:50 2163

Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial ofEnsifentrine for the maintenance treatment of chronic obstructive pulmonary ...

2022-08-19 11:24 1330
1 ... 115116117118119120121 ... 279